Summary
The clinical pharmacology of intermediatedose oral methotrexate (MTX) was studied in nine patients receiving 18 courses of treatment. Serum and urine MTX concentrations were measured by means of a competitive protein binding assay after oral aqueous solution (3 courses), 50-mg tablets (13 courses) or IV drug (2 courses) had been administered in four doses of 100 mg/m2 at 6-h intervals or in four doses of 200 mg/m2 at 6-h intervals and followed by citrovorum factor rescue. Levels above 150 ng/ml (3.3x10-7 M) were maintained throughout all treatment cycles, with rapid disappearance of drug after the last dose. A 100% increase in administered dose resulted in only a 42% increase in the concentration-time level. Methotrexate was absorbed well from both aqueous solutions and 50-mg tablets, but serum levels after 50-mg tablets were only 20% of those achieved after IV administration.
We conclude that significant serum MTX concentrations can be achieved for prolonged periods of time after oral administration of intermediate doses, but that the proportion of drug absorbed is much less than is seen with lower doses.
Similar content being viewed by others
References
Bender RA (1975) Membrane transport of methotrexate (NSC 740) in human neoplastic cells. Cancer Chemother Rep 6:73–82
Burchenal JH, Waring GB, Ellison RR, Reilly HCA (1951) Simple method for determination of levels of amethopterin in blood and urine. Proc Soc Exp Biol Med 78:603–605
Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52:1804–1811
Freeman MV (1958) The fluorimetric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl-pteroylglutamic acid (amethopterin) in man. J Pharmacol Exp Ther 122:154–162
Freeman-Narrod M, Gerstley BJ, Engstrom PF, Bornstein RS (1975) Comparison of serum concentrations of methotrexate after various routes of administration. Cancer 36:1619–1624
Gibaldi M (1977) Biopharmaceutics and clinical pharmacokinetics, 2nd. ed. Lea and Febiger, Philadelphia, p 8
Halprin KM, Fukui K, Okawara A (1971) Blood levels of methotrexate and the treatment of psoriasis. Arch Dermatol 103:243–249
Henderson ES, Adamson RH, Oliverio VT (1965) The metabolic fate of tritiated MTX II. Absorption and excretion in man. Cancer Res 25:1018–1024
Kinkade JM, Vogler WR, Dayton PG (1974) Plasma levels of methotrexate in cancer patients as studied by an improved spectrophotofluorometric method. Biochem Med 10:337–350
Myers CE, Lippman ME, Eliot HM, Chabner BA (1975) Competitive protein binding assay for methotrexate. Proc Natl Acad Sci USA 72:3683–3686
Noble WC, White PM, Baker H (1975) Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis. J Invest Dermatol 64:69–76
Robert F (1977) Cytoxan, adriamycin, methotrexate and folinic acid rescue (CAMFAR) treatment of metastatic adenocarcinoma of the lung. Proc AACR/ASCO 18:281, Abstract C-59
Robert F, Rivera M, Muniz F (1979) Serum concentrations of methotrexate (MTX) during high, intermediate and low dosage schedules. Proc. AACR/ASCO 20:319, Abstract C-118
Stoller, RG, Jacobs SA, Drake JC, Lutz RJ, Chabner BA (1975) Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemother Rep 6:19–24
Tornyos K, Faust H (1978) Oral high-dose methotrexate with citrovorum factor rescue in metastatic squamous cell carcinoma of the lung. Cancer 41:400–402
Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B (1974) Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 34:3487–3491
Zurek WZ, Anderson L, Collins C, Ojima Y, Collins GJ, Sullivan RD (1968) Pharmacologic studies of methotrexate in man. Surg Gynecol Obstet 126:331–338
Author information
Authors and Affiliations
Additional information
Preliminary results previously published in abstract form in the Proceedings, American Association for Cancer Research and Am. Soc Clin Oncology 20:100 (1979) (Abstract 402)
Rights and permissions
About this article
Cite this article
Smith, D.K., Omura, G.A. & Ostroy, F. Clinical pharmacology of intermediate-dose oral methotrexate. Cancer Chemother. Pharmacol. 4, 117–120 (1980). https://doi.org/10.1007/BF00254032
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254032